DiaSorin (OTCMKTS:DSRLF) Shares Gap Up – Should You Buy?

DiaSorin S.p.A. (OTCMKTS:DSRLF) gapped up before the market opened on Monday. The stock had previously closed at $84.12, but opened at $92.00. DiaSorin shares last traded at $92.00, with a volume of 226 shares trading hands.

Analysts Set New Price Targets

DSRLF has been the subject of a number of recent research reports. BNP Paribas Exane downgraded shares of DiaSorin from a “neutral” rating to an “underperform” rating in a research note on Tuesday, July 7th. Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating on shares of DiaSorin in a research report on Tuesday, August 4th. Zacks Research raised DiaSorin from a “strong sell” rating to a “hold” rating in a research report on Friday, October 2nd. Finally, UBS Group cut DiaSorin from a “hold” rating to a “sell” rating in a research note on Wednesday, August 12th. Two research analysts have rated the stock with a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat.com, DiaSorin currently has a consensus rating of “Strong Sell”.

DiaSorin Stock Up 4.3%

The company’s fifty day simple moving average is $85.86 and its 200-day simple moving average is $79.20.

About DiaSorin

DiaSorin S.p.A. is an Italian company specializing in in vitro diagnostics, with a focus on immunodiagnostics and molecular diagnostics. Its products are used by hospitals, clinical laboratories and healthcare providers to support the detection, diagnosis and monitoring of a range of diseases and medical conditions.

The company’s portfolio includes automated immunoassay systems, reagents and diagnostic tests marketed under the LIAISON family, as well as molecular diagnostic platforms and assays.